Citations

Clear

16280 citation(s) found for "Yu, David".

The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments
Clevenger, Carolyn , Karlawish, Jason , Knopman, David S. , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, Marı́a C., Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14335 | PMID 39713939 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. As part of the modified Delphi approach and guideline development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. The workgroup provided a summary of validated instruments to measure symptoms in daily life (including cognition, mood and behavior, and daily function) and to test for signs of cognitive impairment in the office. This article distills this information to provide a resource to support clinicians in the implementation of this approach in clinical practice. The companion articles provide context for primary care and specialty clinicians with regard to how to fit these instruments into the workflow and actions to take when integration of performance on these instruments with clinical profile and clinician judgment support potential cognitive impairment.
Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia
Vargas‐González, Juan‐Camilo , Dimal, Nico , Cortez, Kasey, Heuer, Hilary W. , Forsberg, Leah K. , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R., Grant, Ian , Kantarci, Kejal , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Boxer, Adam L. , Rosen, Howie, Damme, Philip Van , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Van Damme, Philip , Pascual, Belen , Domoto-Reilly, Kimiko , Barmada, Sami , Appleby, Brian S. , Bozoki, Andrea C , Clark, David , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Graff‐Radford, Neill R. , Irwin, David J. , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Boeve, Bradley F. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14448 | PMID 39713899 Get It

Abstract INTRODUCTION Psychotropic medication (PM) use in behavioral‐variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD. METHODS We analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study. We estimated ordinal odds ratio (OOR) of having more PM comparing sporadic and genetic bvFTD. Finally, we explored the neuropsychiatric symptom (NPS) combinations using classification and regression trees (CART). RESULTS We included 263 with sporadic and 193 with genetic bvFTD. The OOR for sporadic bvFTD to be on PM was 1.75 (95% confidence interval: 1.21 to 2.53) for the fully adjusted model. CART revealed the most common NPS combination was apathy + personality changes in 18% of participants. DISCUSSION Participants with sporadic bvFTD were twice as likely to be on PM compared to genetic bvFTD. The reason for increased PM usage in sporadic bvFTD participants should be further investigated. Highlights We report on patients with behavioral variant frontotemporal dementia (bvFTD). We evaluated the psychotropic medication (PM) prescription at baseline in the cohort. Patients with sporadic bvFTD had more prescriptions for PM than genetic patients. The frequency of symptoms combination was different in sporadic and genetic bvFTD.
Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS
Hammers, Dustin B. , Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Gao, Sujuan , Polsinelli, Angelina J. , Kirby, Kala, Dage, Jeffrey L. , Aisen, Paul, Reman, Rema, Joie, Renaud La , Clark, David W. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Grant, Ian , Honig, Lawrence S., Johnson, Erik C. B. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, Marı́a C., Rabinovici, Gil D. , Apostolova, Liana G. , Carrillo, María C. , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Beckett, Laurel , Kirby, Kala, Nudelman, Kelly , Reman, Rema, Lagarde, Julien , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Womack, Kyle , Musiek, Erik , Salloway, Steve , Wolk, S. J. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14439 | PMID 39713873 Get It

Abstract INTRODUCTION Early‐onset Alzheimer's disease (EOAD) manifests prior to the age of 65, and affects 4%–8% of patients with Alzheimer's disease (AD). The current analyses sought to examine longitudinal cognitive trajectories of participants with early‐onset dementia. METHODS Data from 307 cognitively normal (CN) volunteer participants and those with amyloid‐positive EOAD or amyloid‐negative cognitive impairment (EOnonAD) were compared. Cognitive trajectories across a comprehensive cognitive battery spanning 42 months were examined using mixed‐effects modeling. RESULTS The EOAD group displayed worse cognition at baseline relative to EOnonAD and CN groups, and more aggressive declines in cognition over time. The largest effects were observed on measures of executive functioning domains, while memory declines were blunted in EOAD. DISCUSSION EOAD declined 2–4× faster than EOnonAD, and EOAD pathology is not restricted to memory networks. Early identification of deficits is critical to ensure that individuals with sporadic EOAD can be considered for treatment using disease‐modifying medications. Highlights Represents the most comprehensive longitudinal characterization of sporadic EOAD to date. The trajectory of cognitive declines was steep for EOAD participants and worse than for other groups. Executive functioning measures exhibited the greatest declines over time in EOAD.
Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Hammers, Dustin B. , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Gao, Sujuan , Polsinelli, Angelina J. , Kirby, Kala, Dage, Jeffrey L. , Aisen, Paul , Reman, Rema, Joie, Renaud La , Clark, David A. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Grant, Ian , Rogalskı, Emily , Johnson, Erik C. B. , Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Beckett, Laurel , Kirby, Kala, Nudelman, Kelly , Lagarde, Julien , Atri, Alireza , Clark, David, Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Womack, Kyle , Musiek, Erik , Salloway, Steve , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14218 | PMID 39711228 Get It

Abstract INTRODUCTION Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) share similar amyloid etiology, but evidence from smaller‐scale studies suggests that they manifest differently clinically. Current analyses sought to contrast the cognitive profiles of EOAD and LOAD. METHODS Z‐ score cognitive‐domain composites for 311 amyloid‐positive sporadic EOAD and 314 amyloid‐positive LOAD participants were calculated from baseline data from age‐appropriate control cohorts. Z‐ score composites were compared between AD groups for each domain. RESULTS After controlling for cognitive status, EOAD displayed worse visuospatial, executive functioning, and processing speed/attention skills relative to LOAD, and LOAD displayed worse language, episodic immediate memory, and episodic delayed memory. DISCUSSION Sporadic EOAD possesses distinct cognitive profiles relative to LOAD. Clinicians should be alert for non‐amnestic impairments in younger patients to ensure proper identification and intervention using disease‐modifying treatments. Highlights Both early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) participants displayed widespread cognitive impairments relative to their same‐aged peers. Cognitive impairments were more severe for EOAD than for LOAD participants in visuospatial and executive domains. Memory and language impairments were more severe for LOAD than for EOAD participants Results were comparable after removing clinical phenotypes of posterior cortical atrophy (PCA), primary progressive aphasia (lv‐PPA), and frontal‐variant AD.
The Family Anesthesia Experience (FAX): Implementing a Social Support–Focused Wellness Programme Across Multiple Residency Programmes
Martinelli, Susan M. , Tran, Thanh N. , Canter, Courtney , Isaak, Robert S. , Mulaikal, Teresa A., Ladlie, Beth L., Willie, Chelsea, Stahl, David L. , Blanchard, Erin E , Zisblatt, Lara , Hoefnagel, A. L. , Marshall, Julie , Collins, Stephen R., Martin, Timothy W. , Chen, Fei , Ladlie, Beth, Marshall, Julie M , Afroze, Farzana, Jain, Ankit , Keneally, Ryan J.

Mayo Clinic

The Clinical Teacher | December 22, 2024 | Volume: 22 | Issue: 1 | Pages: No page available

10.1111/tct.13853 | PMID 39710581 Get It

ABSTRACT Introduction Lack of social support negatively impacts medical trainees' wellness. Programmes to educate medical trainees and their support persons (SPs) have been developed to improve resident wellness, but implementation of these programmes at other institutions remains unclear. We aimed to demonstrate the feasibility of implementing the Family Anesthesia Experience (FAX) programme across multiple institutions and to assess the programme's utility. Methods FAX includes didactics on wellness, burnout, substance use disorder and institutional resources; a panel of senior residents and their SPs; and small‐group simulations of airway management, common procedures and a high‐fidelity intraoperative code. We assessed the programme qualitatively using semistructured interviews of 20 first year anaesthesiology residents and 20 SPs. Data analysis was performed via a content analysis approach. Results Twelve anaesthesiology programmes of varying size and geographic locations implemented FAX with minor adaptations. Minimal direct costs were incurred for the virtual programme. Participants enjoyed the event overall. Content analysis showed that FAX improved SPs' understanding of residency and communication between SPs and residents, had minimal impact on SPs' stress, reduced residents' interpersonal stress with SPs and modified perceptions on wellness and burnout. We developed a conceptual model in which we propose SPs' understanding and empathy for their residents would improve through FAX, which may improve communication with and support for residents. Conclusion We demonstrated that FAX can be implemented at varying anaesthesiology residency programmes. Family‐oriented educational events like FAX may be an effective approach to improve SPs' understanding of a resident's role, thereby increasing social support for residents.
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Shore, Neal D. , Nielsen, Sarah M. , Esplin, Edward D. , Antonarakis, Emmanuel S. , Barata, Pedro C. , Beltran, Himisha , Bryce, Alan H. , Cookson, Michael S. , Crawford, E. David , Dorff, Tanya B. , George, Daniel J. , Heath, Elisabeth I. , Hussain, Maha , McKay, Rana R. , Ross, Ashley E. , Shen, John , Sieber, Paul , Armstrong, Andrew J. , Antonarakis, Emmanuel S. , Shore, Neal , Beer, Tomasz M , Beltran, Himisha , Bryce, Alan H , Dorff, Tanya , George, Daniel J , Heath, Elisabeth I , Helfand, Brian T. , Hussain, Maha H A , McKay, Rana R , Morgans, Alicia K , Morris, Michael J , Ross, Ashley E , Sartor, A Oliver , Wise, David R , Armstrong, Andrew J , Barata, Pedro , Antonarakis, Emmanuel S , Esplin, Edward D , Antonarakis, Emmanuel S , Beer, Tomasz M. , Morgans, Alicia K. , Morris, Michael J. , Paller, Channing J. , Sartor, Oliver , Smith, Matthew Ryan

Mayo Clinic

JCO Oncology Practice | December 19, 2024 | Volume: 21 | Issue: 6 | Pages: 747-753

10.1200/op-24-00626 | PMID 39700441 Get It

Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
Multicohort Analysis of Bronchial Epithelial Cell Expression in Healthy Subjects and Patients with Asthma Reveals Four Clinically Distinct Clusters
Lee, Ian , Ganesan, Ananthakrishnan , Kalesinskas, Laurynas , Zheng, Hong , Ahn, Haejun C., Christenson, S., Erzurum, Serpil C. , Zein, Joe , Bleecker, Eugene R., Meyers, Deborah A., Fahy, John V. , Israel, Elliot, Jarjour, Nizar N. , Moore, W., Mauger, David T. , Woodruff, Prescott G. , Ortega, Victor E. , Khatri, Purvesh , Zheng, Hong , Lee, Ian , Christenson, Stephanie A. , Castro, M , Wenzel, Sally E , Khatri, Purvesh , Lee, Ian Y , Christenson, Stephanie A , Lee, Ian , Meyers, Deborah A. , Castro, Mario , Israel, Elliot , Wenzel, Sally E. , Levy, Bruce David

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | December 19, 2024 | Volume: 73 | Issue: 1 | Pages: 73-87

10.1165/rcmb.2024-0125oc | PMID 39700523 Get It

Abstract Asthma is a heterogeneous disease with variable presentation and characteristics. There is a critical need to identify underlying molecular endotypes of asthma. We performed the largest transcriptomic analysis of 808 bronchial epithelial cell samples across 11 independent cohorts, including 3 cohorts from the Severe Asthma Research Program. Using seven datasets (218 patients with asthma, 148 healthy control subjects) as discovery cohorts, we identified 505 differentially expressed genes, which we validated in the remaining four datasets. Unsupervised clustering using the 505 differentially expressed genes identified four reproducible clusters of patients with asthma across all datasets, corresponding to healthy control subjects, patients with mild/moderate asthma, and patients with severe asthma with significant differences in several clinical markers of severity, including pulmonary function, Type 2 inflammation, fractional exhaled nitric oxide, and maximum bronchodilator reversibility. Importantly, we found the same clusters in pediatric patients using nasal lavage fluid cells, demonstrating the gene signature and clusters are not confounded by age and are conserved in both lower and upper airways. The four asthma clusters may represent a unifying framework for understanding the molecular heterogeneity of asthma. Further study could potentially enable a precision medicine approach of matching therapies with patients with asthma most likely to benefit.
A Prospective, Randomized, Noninferiority Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation Compared with Standard Ureteroscopy: 30-Day Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett A. , Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Cuellar, David, Cobb, Kaitlan, Barsky, Robert I, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Chi, Thomas , Johnson, Brett , Stern, Karen L , Mueller, Thomas J. , Jones, Loren, White, Mark, Levin, Michael

Mayo Clinic

Journal of Endourology | December 19, 2024 | Volume: 39 | Issue: 1 | Pages: 10-18

10.1089/end.2024.0602 | PMID 39699687 Get It

Purpose: We report the first multicenter, prospective, randomized noninferiority controlled trial of steerable ureteroscopic renal evacuation (SURE) for nephrolithiasis treatment. Materials and Methods: Candidates for laser lithotripsy ≥18 years with ≥1 renal stone ≥7 mm and 7–20 mm stone burden were randomized 1:1 SURE vs ureteroscopy (URS). SURE was performed using the CVAC Aspiration System, a novel steerable irrigation–aspiration catheter. The primary efficacy end point was noninferiority in stone-free rate (SFR) based on zero residual fragments (RFs) 30 days postprocedure on noncontrast computed tomography. Secondary end points were superiority tests, stone clearance (percent stone volume reduction), residual stone volume (RSV), SFR (no RF >2 mm), and SFR (no RF >4 mm) 30 days postprocedure. Results: Of the subjects, 123 were randomized and 101 qualified for efficacy analysis (SURE 46 vs URS 55). Despite randomization, baseline URS stone volume was higher (SURE 485.0 ± 432.5 mm 3 vs URS 713.3 ± 558.5 mm 3 ). The primary noninferiority end point was achieved (SURE SFR 48% vs URS SFR 49%, p = 0.027, −1.3% [90% confidence interval; −18%, 15%]). Stone clearance was significantly higher for SURE vs URS subjects (SURE 96.9 ± 5.6% vs URS 92.9 ± 11.6%, p = 0.036); RSV was significantly lower (SURE 14.3 ± 3 0.9 mm 3 vs URS 70.2 ± 144.9 mm 3 , p = 0.012). SURE stone clearance and RSV were independent of baseline stone volume, but for URS degraded with increasing baseline stone volume. Safety was comparable between groups. Conclusions: SFR for SURE subjects was noninferior compared with URS subjects; stone clearance and RSV were significantly better with SURE, independent of baseline stone volume.
Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study
Ablon, Glynis , Bank, David, Kontis, Theda C., Ibrahim, Sherrif F., Palm, Melanie D., Cox, Sue Ellen , Grunebaum, Lisa D., Goldman, Mitchel P. , Humphrey, Shannon , Coquis-Knezek, Sarah, Grunebaum, Lisa, Rivers, Jason Keller

Mayo Clinic

Dermatologic Surgery | December 18, 2024 | Volume: 51 | Issue: 3 | Pages: 277-283

10.1097/dss.0000000000004470 | PMID 39692332 Get It

BACKGROUND RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A. OBJECTIVE Efficacy/safety of RelaBoNT-A treatment for lateral canthal lines (LCL). METHODS Randomized adults received RelaBoNT-A (30 U/side; n = 230) or placebo (n = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]). Primary end points (Month 1, maximum smile) comprised: composite ≥2-grade responder rate using concurrent LCL severity investigator live assessment (LCL-ILA) and subject live assessment (LCL-SLA); LCL-ILA 0 (none)/1 (mild) responder rate. Subject satisfaction and adverse events were also reported. RESULTS Month 1 composite ≥2-grade responder rates were 51.8% (RelaBoNT-A) and 1.4% (placebo; (p < .001). Month 1 none/mild LCL-ILA responder rates were 87.2% (RelaBoNT-A) and 11.9% (placebo; p < .001). Onset was reported Day 1 by 34%. At Month 6, LCL-ILA responder rates for RelaBoNT-A remained at 23.3% (none/mild) and 35.9% (≥1-grade improvement). Median return to baseline severity was 24.7 weeks; 64% (RelaBoNT-A group) had not returned to baseline at Month 6. RelaBoNT-A satisfaction was high through Month 6 (71%). Mild/moderate treatment-related adverse events occurred in 6.1% (RelaBoNT-A) and 5.5% (placebo). CONCLUSION RelaBoNT-A (60 U) treatment provided statistically significant improvement of moderate-to-severe LCL. One-third of subjects reported onset within 1 day and improvements were maintained through Month 6. Treatment satisfaction was high. RelaBoNT-A was well tolerated.
CT perfusion for lesion-symptom mapping in large vessel occlusion ischemic stroke
Garrard, James , Neuhaus, Ain , Carone, Davide , Zarrintan, Armin , Harston, George , Brinjikji, Waleed , Kallmes, David F. , Garrard, James William , Zarrintan, Armin , Brinjikji, Waleed , Joly, Olivier , Rabinstein, Alejandro A. , Huynh, Thien

Mayo Clinic

Journal of NeuroInterventional Surgery | December 18, 2024 | Volume: 18 | Issue: 1 | Pages: 149-154

10.1136/jnis-2024-022501 | PMID 39694810 Get It

Background Identifying eloquent regions associated with poor outcomes based on CT perfusion (CTP) may help inform personalized decisions on selection for endovascular therapy (EVT) in patients with large vessel occlusion (LVO) ischemic stroke. This study aimed to characterize the relationship between CTP-defined hypoperfusion and National Institutes of Health Stroke Scale (NIHSS) subitem deficits. Methods Patients with anterior circulation LVO, baseline CTP, itemized NIHSS at presentation and 24 hours were included. CTP was analyzed using e-CTP (Brainomix, UK). Time to maximal contrast (Tmax) prolongation was defined as >6 s, and penumbra as the difference between Tmax and ischemic core (relative cerebral blood flow<30%). Voxel-lesion-symptom mapping was performed using sparse canonical correlation analysis. For each NIHSS subitem, and total NIHSS, the associations were plotted between Tmax voxels with baseline NIHSS, and penumbra voxels with delta NIHSS (24 hours minus baseline). Results This study included 171 patients. Total NIHSS was predicted by hypoperfusion in left frontal cortex and subcortical white matter tracts. Voxels associated with neurological recovery were symmetrical and subcortical. Limb deficits were associated with respective motor cortex regions and descending motor tracts, with negative correlation within the contralateral hemispheres. A similar but smaller cluster of voxels within the penumbra was associated with NIHSS improvement. Language impairment correlated with left frontal cortex and superior temporal gyrus voxels. With the exception of dysarthria, significant associations were observed and more diffusely distributed in all other NIHSS subitems. Conclusions These results demonstrate the feasibility of hypoperfusion-to-symptom mapping in LVO. Symptom-based mapping from presenting imaging could refine treatment decisions targeting specific neurological deficits.